The latest price target for BioCryst Pharma (NASDAQ:BCRX) was reported by JMP Securities on August 6, 2024. The analyst firm set a price target for $16.00 expecting BCRX to rise to within 12 months (a possible 98.02% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for BioCryst Pharma (NASDAQ:BCRX) was provided by JMP Securities, and BioCryst Pharma maintained their market outperform rating.

The last upgrade for BioCryst Pharmaceuticals Inc happened on September 18, 2023 when RBC Capital raised their price target to $10. RBC Capital previously had a sector perform for BioCryst Pharmaceuticals Inc.

The last downgrade for BioCryst Pharmaceuticals Inc happened on August 8, 2022 when Oppenheimer changed their price target from N/A to N/A for BioCryst Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioCryst Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioCryst Pharma was filed on August 6, 2024 so you should expect the next rating to be made available sometime around August 6, 2025.

While ratings are subjective and will change, the latest BioCryst Pharma (BCRX) rating was a maintained with a price target of $15.00 to $16.00. The current price BioCryst Pharma (BCRX) is trading at is $8.08, which is out of the analyst’s predicted range.